JP2007504132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504132A5 JP2007504132A5 JP2006524705A JP2006524705A JP2007504132A5 JP 2007504132 A5 JP2007504132 A5 JP 2007504132A5 JP 2006524705 A JP2006524705 A JP 2006524705A JP 2006524705 A JP2006524705 A JP 2006524705A JP 2007504132 A5 JP2007504132 A5 JP 2007504132A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- daltons
- molecular weight
- group
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 210000004027 cells Anatomy 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229920001477 hydrophilic polymer Polymers 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 102000005763 Thrombopoietin Receptors Human genes 0.000 claims 4
- 108010070774 Thrombopoietin Receptors Proteins 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 4
- 229920001451 Polypropylene glycol Polymers 0.000 claims 2
- 229940043230 Sarcosine Drugs 0.000 claims 2
- 108010077895 Sarcosine Proteins 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229940000635 beta-Alanine Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine zwitterion Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 2
- 210000001772 Blood Platelets Anatomy 0.000 claims 1
- 102100016492 CD34 Human genes 0.000 claims 1
- 108060001251 CD34 Proteins 0.000 claims 1
- 210000003593 Megakaryocytes Anatomy 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920002397 Thermoplastic olefin Polymers 0.000 claims 1
- 102000036902 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-Naphthyl)-Alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 claims 1
Claims (21)
- 配列(H−IEGPTLRQ(2−Nal)LAARX10)2K−NH2(ここで、X10はサルコシンまたはβ−アラニンからなる群から選択される)を含んでなるトロンボポエチン受容体に結合する化合物。
- 化合物が親水性ポリマーに共有結合している請求項1に記載の化合物。
- 親水性ポリマーが約500と約40,000ダルトンの間の平均分子量を有する請求項2に記載の化合物。
- 親水性ポリマーが約5,000と約20,000ダルトンの間の平均分子量を有する請求項2に記載の化合物。
- 親水性ポリマーがポリエチレングリコール、ポリプロピレングリコール、ポリ乳酸およびポリグリコール酸からなる群から選択される請求項2に記載の化合物。
- 化合物がポリエチレングリコールに共有結合している請求項5に記載の化合物。
- 化合物の二量体サブユニットの各々が親水性ポリマーに共有結合している請求項1に記載の化合物。
- 請求項1に記載の化合物を医薬的に許容され得るキャリアと組み合わさった状態で含んでなる医薬組成物。
- 請求項1に記載の化合物を有効成分として含んでなるトロンボポエチンアゴニストによる処置に感受性の疾患に罹っている患者の処置のための製薬学的製剤。
- ポリエチレングリコールとポリプロピレングリコールからなる群から選択される約500と約20,000ダルトンの間の分子量を有し、かつ、非置換であるか、あるいはアルコキシあるいはアルキル基により置換され、そして前記アルコキシあるいはアルキル基が5個未満の炭素原子を有するポリマーの少なくとも1つにカップリング剤によりカップリングされた請求項1に記載の化合物を含んでなる生理学的に活性な、実質的に非免疫原性の水溶性ポリペプチド組成物。
- ポリマーが約750と約15,000ダルトンの間の平均分子量を有する請求項10に記載のポリペプチド組成物。
- ポリマーが約5,000と約10,000ダルトンの間の平均分子量を有する請求項10に記載のポリペプチド組成物。
- ポリマーがポリエチレングリコールである請求項10に記載のポリペプチド組成物。
- 請求項10に記載の化合物と医薬的に許容され得るキャリを含んでなる実質的に非免疫原性の水溶性ポリペプチド組成物。
- 細胞を配列(H−IEGPTLRQ(2−Nal)LAARX10)2K−NH2(こ
こで、X10はサルコシンまたはβ−アラニンからなる群から選択される)を含む化合物
の有効量と接触させることを含んでなる、細胞のトロンボポエチン受容体の活性化方法。 - 細胞がヒト巨核球、血小板またはCD34+細胞を含んでなる請求項15に記載の方法。
- 細胞がTPO依存性細胞を含んでなる請求項15に記載の方法。
- (1)約8000ダルトン未満の分子量と、
(2)約100μM以下のIC50により表されるトロンボポエチン受容体への結合親和性を有し、かつ、下記アミノ酸配列:
X9X8GX1X2X3X4X5X6X7
(ここで、X9はA、C、E、G、I、L、M、P、R、Q、S、T、またはVであり;X8はA、C、D、E、K、L、Q、R、S、T、またはVであり、X1はC、L、M、P、Q、Vであり;X2はF、K、L、N、Q、R、S、TまたはVであり;X3はC、F、I、L、M、R、S、VまたはWであり;X4は20個の遺伝的にコーディングされたL−アミノ酸のいずれかであり;X5はA、D、E、G、K、M、Q、R、S、T、VまたはYであり;X7はC、G、I、K、L、M、N、RまたはVであり、そしてX6はβ−(2−ナフチル)アラニンである)
を含んでなる、トロンボポエチン受容体に結合する化合物。 - アミノ酸配列が環化されている請求項18に記載の化合物。
- アミノ酸配列が二量化されている請求項18に記載の化合物。
- 前記化合物がIEGPTLRQ(2−Nal)LAARAのアミノ酸配列を含んでなる請求項18に記載の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49874003P | 2003-08-28 | 2003-08-28 | |
US60/498,740 | 2003-08-28 | ||
PCT/US2004/026422 WO2005023834A2 (en) | 2003-08-28 | 2004-08-13 | Peptides and compounds that bind to thrombopoietin receptors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007504132A JP2007504132A (ja) | 2007-03-01 |
JP2007504132A5 true JP2007504132A5 (ja) | 2007-09-20 |
JP4848277B2 JP4848277B2 (ja) | 2011-12-28 |
Family
ID=34272720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006524705A Active JP4848277B2 (ja) | 2003-08-28 | 2004-08-13 | 受容体に結合するペプチドおよび化合物 |
Country Status (33)
Country | Link |
---|---|
US (1) | US7576056B2 (ja) |
EP (1) | EP1675606B1 (ja) |
JP (1) | JP4848277B2 (ja) |
KR (2) | KR20120078742A (ja) |
CN (2) | CN1871022B (ja) |
AR (1) | AR045530A1 (ja) |
AU (1) | AU2004270656B2 (ja) |
BR (1) | BRPI0414008B8 (ja) |
CA (1) | CA2537421C (ja) |
CY (1) | CY1118965T1 (ja) |
DK (1) | DK1675606T3 (ja) |
EA (1) | EA009286B1 (ja) |
EC (1) | ECSP066396A (ja) |
ES (1) | ES2626107T3 (ja) |
HK (1) | HK1096873A1 (ja) |
HR (1) | HRP20170810T1 (ja) |
HU (1) | HUE032370T2 (ja) |
IL (1) | IL173965A (ja) |
IS (1) | IS8300A (ja) |
LT (1) | LT1675606T (ja) |
ME (1) | ME00313B (ja) |
MX (1) | MXPA06002292A (ja) |
NO (1) | NO344233B1 (ja) |
NZ (1) | NZ545455A (ja) |
PL (1) | PL1675606T3 (ja) |
PT (1) | PT1675606T (ja) |
RS (2) | RS56387B1 (ja) |
SG (1) | SG131110A1 (ja) |
SI (1) | SI1675606T1 (ja) |
TW (1) | TWI348375B (ja) |
UA (1) | UA82710C2 (ja) |
WO (1) | WO2005023834A2 (ja) |
ZA (1) | ZA200602495B (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
SI2319928T1 (sl) | 1998-10-23 | 2013-08-30 | Kirin-Amgen, Inc. | Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost |
AU2003275077B2 (en) * | 2002-09-18 | 2010-02-04 | Ortho-Mcneil Pharmaceutical, Inc. | Methods of increasing platelet and hematopoietic stem cell production |
US20040149235A1 (en) * | 2002-10-04 | 2004-08-05 | Pogue Albert S. | Apparatus and method for removal of waste from animal production facilities |
US7723295B2 (en) * | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
RS56387B1 (sr) | 2003-08-28 | 2017-12-29 | Ortho Mcneil Pharm Inc | Peptidi i jedinjenja koja se vežu za trombopoetinski receptor |
US7615533B2 (en) | 2004-08-16 | 2009-11-10 | Janssen Pharmaceutica N.V. | TPO peptide compounds for treatment of anemia |
EP1986677A2 (en) * | 2006-01-25 | 2008-11-05 | Amgen Inc. | Thrombopoietic compounds |
JP2009526841A (ja) * | 2006-02-14 | 2009-07-23 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Tpoペプチド化合物及び薬学的組成物の貧血症の処置における使用 |
TWI458488B (zh) * | 2006-02-14 | 2014-11-01 | Janssen Pharmaceutica Nv | Tpo胜肽化合物及醫藥組成物於治療貧血之用途 |
US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
MX2010013281A (es) * | 2008-06-03 | 2010-12-21 | Janssen Pharmaceutica Nv | Peptido mimetico de trombopoyetina para prevenir trastornos hematologicos asociados con el tratamiento del cancer. |
JP5709113B2 (ja) | 2011-06-23 | 2015-04-30 | 株式会社島津製作所 | 分岐型両親媒性ブロックポリマー、それを用いた分子集合体及び薬剤搬送システム |
BR112020001367A2 (pt) * | 2017-07-26 | 2020-08-11 | Janssen Pharmaceutica N.V. | métodos de proteção da integridade vascular induzida por terapia de radiação direcionada |
CA3127455A1 (en) | 2019-01-25 | 2020-07-30 | Janssen Pharmaceutica Nv | Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments |
US11273203B2 (en) | 2019-01-25 | 2022-03-15 | Janssen Pharmaceutica Nv | Methods of mitigating toxic effects of vesicants and caustic gas |
WO2020154637A1 (en) | 2019-01-25 | 2020-07-30 | Janssen Pharmaceutica Nv | Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure |
US20230104658A1 (en) | 2021-10-01 | 2023-04-06 | Janssen Pharmaceutica Nv | Methods of increasing progenitor cell production |
WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5326558A (en) * | 1989-08-08 | 1994-07-05 | Genetics Institute, Inc. | Megakaryocytopoietic factor |
IL96477A0 (en) | 1989-12-01 | 1991-08-16 | Amgen Inc | Megakaryocyte production |
DK167813B1 (da) * | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
US5571508A (en) | 1989-12-18 | 1996-11-05 | Amrad Corporation Limited | Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor |
IT1241395B (it) | 1990-04-02 | 1994-01-10 | Eniricerche Spa | Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria |
US5141851A (en) * | 1990-04-18 | 1992-08-25 | Board Of Regents, The University Of Texas System | Isolated farnesyl protein transferase enzyme |
US5250732A (en) * | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
ATE222500T1 (de) | 1992-06-11 | 2002-09-15 | Alkermes Inc | Enythropoietin enthaltendes arzneimittelabgabesystem |
EP0945504A3 (en) * | 1992-12-11 | 1999-12-08 | The University Of Florida | Materials and method for control of pests |
WO1995011922A1 (en) | 1993-10-29 | 1995-05-04 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
SG47030A1 (en) | 1994-01-03 | 1998-03-20 | Genentech Inc | Thrombopoietin |
SG79882A1 (en) | 1994-02-14 | 2001-04-17 | Kirin Brewery | Protein having tpo activity |
NZ281482A (en) | 1994-02-14 | 2000-09-29 | Univ Washington | The stimulation of erythropoiesis using thrombopoietin and erythropoietin |
WO1995021919A2 (en) | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
NZ271230A (en) | 1994-02-14 | 1998-03-25 | Zymogenetics Inc | Hematopoietic proteins, production and use |
DK0690127T3 (da) | 1994-03-31 | 1999-05-03 | Amgen Inc | Sammensætninger og fremgangsmåder til stimulering af megakaryocytvækst og -differentiering |
US5571686A (en) | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
CA2180021A1 (en) * | 1994-11-04 | 1996-05-17 | Yoichi Kawashima | Novel 1,3-dialkylurea derivatives having a hydroxyl group |
US5641655A (en) | 1994-11-30 | 1997-06-24 | Zymogenetics, Inc. | Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide |
WO1996017062A1 (en) | 1994-11-30 | 1996-06-06 | Zymogenetics, Inc. | Low molecular weight thrombopoietin |
ES2276401T3 (es) | 1995-04-26 | 2007-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Proteinas de fusion g-csf tpo. |
US6251864B1 (en) * | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
ES2303338T3 (es) * | 1995-06-07 | 2008-08-01 | Glaxo Group Limited | Peptidos y compuestos que se unen a un receptor de trombopoyetina. |
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6060052A (en) * | 1995-10-30 | 2000-05-09 | Systemix, Inc. | Methods for use of Mpl ligands with primitive human hematopoietic stem cells |
US5932546A (en) * | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
AU771460B2 (en) | 1999-09-24 | 2004-03-25 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
BR0116447B1 (pt) * | 2000-12-22 | 2014-04-29 | Ipsen Mfg Ireland Ltd | Processo para a síntese de peptídeos análogos de LHRH tendo um resíduo de triptofano |
WO2002078612A2 (en) | 2001-04-02 | 2002-10-10 | Euro-Celtique S.A. | Thrombopoietin (tpo) synthebody for stimulation of platelet production |
AU2003275077B2 (en) * | 2002-09-18 | 2010-02-04 | Ortho-Mcneil Pharmaceutical, Inc. | Methods of increasing platelet and hematopoietic stem cell production |
RS56387B1 (sr) | 2003-08-28 | 2017-12-29 | Ortho Mcneil Pharm Inc | Peptidi i jedinjenja koja se vežu za trombopoetinski receptor |
-
2004
- 2004-08-13 RS YU20060141A patent/RS56387B1/sr unknown
- 2004-08-13 KR KR1020127014067A patent/KR20120078742A/ko not_active Application Discontinuation
- 2004-08-13 ME MEP-2008-485A patent/ME00313B/me unknown
- 2004-08-13 LT LTEP04781153.4T patent/LT1675606T/lt unknown
- 2004-08-13 ES ES04781153.4T patent/ES2626107T3/es active Active
- 2004-08-13 US US10/918,561 patent/US7576056B2/en active Active
- 2004-08-13 WO PCT/US2004/026422 patent/WO2005023834A2/en active Application Filing
- 2004-08-13 NZ NZ545455A patent/NZ545455A/en unknown
- 2004-08-13 EA EA200600477A patent/EA009286B1/ru unknown
- 2004-08-13 RS YUP-2006/0141A patent/RS20060141A/sr unknown
- 2004-08-13 SG SG200701488-9A patent/SG131110A1/en unknown
- 2004-08-13 UA UAA200602523A patent/UA82710C2/uk unknown
- 2004-08-13 HU HUE04781153A patent/HUE032370T2/en unknown
- 2004-08-13 CN CN2004800314520A patent/CN1871022B/zh active Active
- 2004-08-13 EP EP04781153.4A patent/EP1675606B1/en active Active
- 2004-08-13 MX MXPA06002292A patent/MXPA06002292A/es active IP Right Grant
- 2004-08-13 PL PL04781153T patent/PL1675606T3/pl unknown
- 2004-08-13 AU AU2004270656A patent/AU2004270656B2/en active Active
- 2004-08-13 CN CN201110134196.XA patent/CN102241742B/zh active Active
- 2004-08-13 DK DK04781153.4T patent/DK1675606T3/en active
- 2004-08-13 JP JP2006524705A patent/JP4848277B2/ja active Active
- 2004-08-13 SI SI200432391A patent/SI1675606T1/sl unknown
- 2004-08-13 PT PT47811534T patent/PT1675606T/pt unknown
- 2004-08-13 BR BRPI0414008A patent/BRPI0414008B8/pt active IP Right Grant
- 2004-08-13 CA CA2537421A patent/CA2537421C/en active Active
- 2004-08-13 KR KR1020067003755A patent/KR101183875B1/ko not_active IP Right Cessation
- 2004-08-27 AR ARP040103101A patent/AR045530A1/es active IP Right Grant
- 2004-08-27 TW TW093125674A patent/TWI348375B/zh active
-
2006
- 2006-02-14 IS IS8300A patent/IS8300A/is unknown
- 2006-02-24 EC EC2006006396A patent/ECSP066396A/es unknown
- 2006-02-27 IL IL173965A patent/IL173965A/en active IP Right Grant
- 2006-03-24 NO NO20061346A patent/NO344233B1/no unknown
- 2006-03-27 ZA ZA200602495A patent/ZA200602495B/en unknown
-
2007
- 2007-04-16 HK HK07103946.2A patent/HK1096873A1/xx not_active IP Right Cessation
-
2017
- 2017-05-30 HR HRP20170810TT patent/HRP20170810T1/hr unknown
- 2017-06-15 CY CY20171100628T patent/CY1118965T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007504132A5 (ja) | ||
Zhou et al. | Advances and biomedical applications of polypeptide hydrogels derived from α‐amino acid N‐carboxyanhydride (NCA) polymerizations | |
HRP20170810T1 (hr) | Peptidi i spojevi koji se vežu za receptore trombopoietina | |
Roy et al. | Bioadhesive polymeric platforms for transmucosal drug delivery systems–a review | |
JP6309980B2 (ja) | 抗バイオフィルム剤を制御放出するためのナノ粒子及びその使用方法 | |
EP1713450B1 (en) | Rapidly dissolving film for delivery of an active agent | |
JP6518588B2 (ja) | 歯の障害を治療するための組成物の製造方法 | |
Gao et al. | Enamel remineralization via poly (amido amine) and adhesive resin containing calcium phosphate nanoparticles | |
US20130030359A1 (en) | Dipeptide-based prodrug linkers for aromatic amine-containing drugs | |
JP2003113113A5 (ja) | ||
EP1968638B1 (en) | Controlled release gels | |
JP2003525912A5 (ja) | ||
ZA200603950B (en) | Pharmaceutical formulations for the sustained release of one or more active principles and applications thereof, such as therapeutic applications | |
JP2009504650A5 (ja) | ||
JP2007530441A5 (ja) | ||
AU2015205438B2 (en) | Peptide dendrimers comprising fibrinogen-binding peptides | |
JP2010505444A5 (ja) | ||
EP2316490A3 (en) | Methods and compositions for enhanced delivery of bioactive molecules | |
CA2594183A1 (en) | Water-absorbent adhesive compositions and associated methods of manufacture and use | |
RU2007131504A (ru) | Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r) | |
JP2010513327A5 (ja) | ||
JP2005058499A (ja) | 生体材料 | |
JP2006519782A5 (ja) | ||
JP5281358B2 (ja) | 高分子、経上皮吸収促進剤、及び医薬用製剤 | |
JP2003504312A5 (ja) |